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Running heading: Attributable fraction of sepsis for trial design 
Abstract 
Purpose: 
Nearly all sepsis trials report no statistically significant difference in mortality. The 
attributable fraction of deaths due to sepsis (AFsepsis) may be an important, yet 
overlooked consideration. We derived AFsepsis and explored the effect of 
incorporating AFsepsis into sample size calculations.  
Materials and Methods:  
We derived AFsepsis with a matched cohort study using consecutive admissions to 
adult general intensive care units (ICUs) in England (n=614,509). Cases were ICU 
patients with sepsis and the two controls were ICU-non-sepsis controls, matched for 
propensity to have sepsis and age-sex-matched general population. The primary 
exposure was sepsis. The primary outcome was hospital mortality. We generated 
sample size graphs, by varying control group mortality (10%-60%), relative risk 
reduction (0-1), for 80% power and 5% alpha. We then compared AFsepsis derived 
sample sizes with sample size calculations from published sepsis trials.  
Results: 
AFsepsis was 15%(95%CI:14%-16%) compared with propensity matched ICU-non-
sepsis controls and 93%(95%CI:92%-93%) compared with age-sex-matched general 
population controls. When comparing AFsepsis derived sample sizes with sample 
size calculations from 18 trials meeting our selection criteria, these calculations 
assumed very high AFsepsis and/or very effective treatments.  
Conclusions:  
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Estimating trial specific AFsepsis to inform sample size calculations could be an 
additional step in sepsis trial design.  
Key words: Sepsis; Attributable fraction; Randomized Controlled Trial; Sample 
size 
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Introduction 
Sepsis [1] is common and is associated with a hospital mortality of 18% to 
33% [2]. Numerous sepsis randomized clinical trials (RCTs) that do not demonstrate 
a statistically significant difference in the primary end point [3] may be explained by 
treatment response variations seen within trial populations [4-7] and differences in 
sepsis pathobiology [3, 8]. In addition to identifying novel, more effective therapies, 
there may be opportunities during design to improve the sensitivity of RCTs [9].  
These trial design modifications have generally focused on enrolling sepsis patients 
at high risk of death, accounting for risk of death in the analysis, excluding patients 
with, for example, cancer or cirrhosis, whose risk of death is due to their comorbidity, 
or enriching the population with patients susceptible to the intervention based on its 
mechanism [6, 9]. 
In this paper, we present a novel analysis of sepsis RCTs using the 
attributable fraction of deaths due to sepsis (AFsepsis) approach [10, 11].  The 
hypothesis is that risk factors for sepsis including age, sex and comorbidities are 
also risk factors for death in critically ill patients regardless of the aetiology of their 
critical illness.  If only deaths in the attributable fraction are preventable with a sepsis 
therapy and this fraction is less than 100%, larger sample sizes may be needed to 
detect plausible treatment effects.  
Materials and Methods 
Conceptual approach 
The interventions tested in sepsis RCTs are developed based on dominant 
biological pathways observed in sepsis [3]. The interventions’ ability to reduce risk of 
death is defined using either absolute or relative risk reduction (RRR). The standard 
approach for sample size estimation in RCTs assumes a RRR across 100% of 
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deaths with the disease. If the control group mortality in a sepsis RCT is 40% and we 
expect the drug to have 20% RRR, then treated patients will have a mortality of 32% 
and 564 patients per group would be required with typical assumptions of 80% 
power and 5% alpha to detect this effect.  The AFsepsis approach explores the 
possibility that, for illustration, only 50% of deaths are attributable to sepsis and 
assumes that only these deaths are affected by treatments for sepsis and that there 
are no placebo responders [10]. If the RRR of 20% applies only to the attributable 
deaths, the effective RRR would reduce to 10% and will require 2311 patients per 
group in this RCT. After empiric estimation of AFsepsis, we compared the sample 
size estimates between the standard and the AFsepsis approach across a range of 
AFsepsis, control group mortalities and treatment effectiveness amongst attributable 
deaths (effective RRR) using examples from published sepsis RCTs [12, 13]. 
Although intuitive and often discussed, the attributable mortality from sepsis-related 
critical illness has not been estimated for Sepsis-3 criteria [1, 14], whilst attributable 
mortality and morbidity estimates from ICU acquired infections highlight that these 
may be quite low [15-17]. 
Study design and data source 
We performed a matched cohort study with cases that met Sepsis-3 criteria 
[1] (eTable1 [18]) and controls that were either non-septic critically ill patients or 
general population to estimate the range of AFsepsis. For sepsis cases and non-
septic critically ill controls, we used the Intensive Care National Audit & Research 
Centre (ICNARC) Case Mix Programme Database (CMPD) [19] (Further details are 
reported in eMethods).  
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Rationale for controls 
Estimating the attributable risk of sepsis requires careful selection of controls and 
attention to confounding variables.  We attempted to estimate the bounds of 
AFsepsis and AFseptic shock by using general population and non-septic critically ill 
controls.  Population controls will estimate the upper bound of the AFsepsis as they 
reflect the best-case scenario that a treatment returns patients admitted to the ICU 
with sepsis to the mortality that patients of similar age and sex would incur.  Since 
unmeasured risk factors for sepsis in the population are also predictors of 
mortality[20], this assumption is optimistic. The non-septic critically ill controls will 
estimate the lower bound of the AFsepsis as they reflect a worst-case scenario that 
a treatment returns patients admitted to the ICU with sepsis to the mortality that non-
septic critically ill patients of similar age, sex, comorbidity and surgical status would 
incur.  Since non-septic critically ill controls incur mortality risk for unique reasons 
due to their reason for ICU admission and severity of illness, this estimate of 
AFsepsis is likely to be an under-estimate. Therefore, while it is unknown whether an 
effective sepsis therapy will return patients to a mortality trajectory similar to the 
population at large or to a general ICU population, we believe that the AFsepsis 
likely falls in this range. This approach to estimate bounds of AFsepsis is similar to 
that used for estimating the magnitude of cardiovascular events in sepsis survivors 
[21].  
Analyses 
The primary exposure was sepsis. The primary outcome was acute hospital 
mortality. All analyses presented as ‘sepsis’ included the subpopulation with septic 
shock. In Sepsis-3 definitions, as septic shock is considered a subset of sepsis with 
greater risk of death than sepsis alone[14], we replicated all the analyses for this 
 7 
subpopulation. Amongst the 654,918 ICU admissions, we excluded patients with 
readmissions (0.05%), patients with missing data on acute illness severity (3.9%), 
and acute hospital mortality (0.3%), resulting in a cohort of 614,509 ICU admissions 
for complete case analyses (eFigure1). 
Estimating AFsepsis and rationale for propensity matching 
Propensity-score methods can be used in a matched cohort study design, to 
estimate the causal effects of sepsis by balancing sepsis and non-septic controls on 
a set of observed baseline covariates [11, 22]. To estimate the mortality of non-
septic critically ill patients we identified a population similar to sepsis based on a 
propensity model with age, sex, severe comorbidity defined using Acute Physiology 
And Chronic Health Evaluation (APACHE II method), and surgical status, assuming 
AFsepsis is constant across different baseline risks  [10, 11]. Since the overall goal 
was to estimate the independent risk of death attributable to sepsis, we did not 
incorporate acute physiologic derangement which likely mediates the effects of 
sepsis on hospital mortality. Further details of propensity methods and rationale for 
sensitivity analysis to estimate AFsepsis and AFseptic shock are reported in e-
methods.  
For population controls, age- and sex-specific expected probabilities of death 
for the general population of England in 2014 were obtained from the Office for 
National Statistics [23]. We used the shortest timeframe available, one-year risk of 
death, to estimate the hospital mortality that could be expected by a treatment that 
reduced AFsepsis to age- and sex-matched population norms. 
Comparing AFsepsis based sample size estimates to standard approach 
In sepsis RCTs, as all patients have the exposure sepsis, AFsepsis could be 
used for sample size estimations [10]. We derived sample sizes for the estimated 
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range of AFsepsis [10], by varying the expected control group mortality between 
10% and 60%, the effective RRR between 0 and 1, for typical assumptions of 80% 
power, 5% alpha and their corresponding constants from normal distribution.   
For illustrating how change in AFsepsis within a trial population could 
influence power and sample size calculation of trials, we identified parallel group 
sepsis RCTs, published since 2007, testing a single intervention, with mortality as 
the primary outcome and included in two recent meta-analyses [12, 13]. We chose 
parallel group RCTs, as there are additional assumptions involved in other RCT 
designs for sample size calculations [24]. We explored patters of inclusion and 
exclusion criteria used in these RCTs. We then extracted control group mortality, 
RRR, power and alpha that informed standard sample size calculations from these 
RCTs for exploring the impact of AFsepsis estimations. If trials used absolute risk 
reduction, then the corresponding RRR was derived. 
Reported p values are two-sided and p values less than 0.05 were considered 
statistically significant. All analyses were performed using Stata/SE version 14 
(StataCorp LP, College Station, TX). 
Results 
Patient characteristics  
Amongst 614,509 ICU admissions with 179,717 sepsis and 36,838 septic 
shock cases, we matched 179,704 sepsis and 36,833 septic shock cases to ICU-
non-sepsis controls, propensity score balanced on age, sex, severe comorbidity and 
surgical status. Sepsis patients had a greater risk of death compared to propensity 
matched non-sepsis ICU controls (hospital mortality 32% vs 27%; risk ratio 1.18; 
95% CI (1.17% - 1.19%); p<0.001). Similarly, septic shock patients had a greater risk 
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of death compared to propensity matched non-sepsis ICU controls (hospital mortality 
56% vs 28%; risk ratio 1.99; 95% CI (1.95 - 2.03); p<0.001) (Figure-1 and Table-1). 
Range of AFsepsis and AFseptic shock 
Using ICU-non-sepsis controls, AFsepsis was 15.2% (95%CI 14.4%-16.1%) 
and AFseptic shock was 49.8% (95%CI 48.8%-50.7%). Compared with age- and 
sex-matched general population controls, AFsepsis was 92.5% (95%CI 92.3%-
92.7%) and AFseptic shock was 94.6% (95%CI 94.3%-94.9%) (Figure-1).  
Sepsis patients without comorbidities had a greater risk of death compared to 
propensity matched non-sepsis ICU controls without comorbidities (hospital mortality 
29% vs 24%; risk ratio 1.18; 95% CI (1.16 - 1.19); p<0.001) and the AFsepsis was 
similar to the overall sepsis population 15.0% (95%CI 13.9%-15.9%).  Septic shock 
patients without comorbidities had a greater risk of death compared to propensity 
matched non-sepsis ICU controls without comorbidities (hospital mortality 52% vs 
25%; risk ratio 2.12; 95% CI (2.07 - 2.17); p<0.001) and the AFseptic shock was also 
was similar to the overall septic shock population 52.8% (95%CI 51.7%-53.9%). In 
the posthoc sensitivity analysis estimating AFSepsis and AFseptic shock excluding 
patients with active treatment withdrawn 12 hours of ICU admission, we observed a 
small increase in AFsepsis to 17.2% (95% CI: 15.7% – 18.9%) and small decrease 
in AFseptic shock to 44.5% (95% CI 42.6% – 46.4%), when compared to primary 
analysis (eTable-2). 
Comparing AFsepsis based sample size estimates to standard approach  
Amongst the trials included in the two systematic reviews [12, 13], 18 RCTs 
met our inclusion criteria (eTable3 and eTable4). Trial inclusion criteria had infection, 
two or more systemic inflammatory response syndrome and organ dysfunction as 
key inclusion criteria. The exclusion criteria varied in trials and could be categorized 
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into generic (such as unlikely to survive beyond 24 hours) and intervention specific 
(such as coagulopathy) (eTable3). For sample size calculations in these RCTs, the 
median (interquartile range) control group mortality used was 44% (37% - 50%) and 
RRR was 20% (20% - 38%). Most trials aimed for 80% power and 5% alpha. The 
sample size per group varied between 64 to 800 patients (eFigure2 and eTable4). At 
AFsepsis=93%, the effective RRR is very similar to the RRR used in the sample size 
calculations. At AFsepsis=15% and AFsepsis=54%, the effective RRR is reduced to 
that fraction of the RRR used for sample size estimates and significantly reduces the 
statistical power of these trials (Figure-2).  For any fixed combinations of control 
group mortality and effective RRR, the sample size will decrease with increase in 
AFsepsis (Figure-3). Similarly, for any AFsepsis value, the sample size will decrease 
with increase in effective RRR (Figure-3). Higher the control group mortality, lower 
will be the sample size for any combination of AFsepsis and effective RRR (Figure-
3). 
Discussion 
We show that AFsepsis in critically ill patients varies between 15% and 93% 
and the higher AFseptic shock is consistent with greater risk of death subset 
highlighted by Sepsis-3 definitions [14]. As AFsepsis is likely to be less than 100% 
even with the best case-scenario, our analyses illustrate that existing RCTs could be 
considered as underpowered except when most deaths are attributable to sepsis, 
and the treatment is extremely effective, under the key assumption that only 
AFsepsis deaths are affected by treatments for sepsis. The key interpretation and 
value of our methodological study is that, accounting for AFsepsis in trial populations 
could to improve the sensitivity of future sepsis RCTs. 
 11 
All RCTs have inclusion and exclusion criteria, which serves to identify 
patients with the illness and specifically exclude patients who are either unlikely to 
benefit or have a greater likelihood of harm from the trial treatment [9, 25]. The 
sepsis RCTs mainly differ in terms of their exclusion criteria (eTable-3) [26], with 
similar inclusion criteria [27]. Therefore, we do not suggest that these principles are 
completely ignored in published sepsis trials where, for example, patients with 
metastatic cancer and cirrhosis are frequently excluded presumably because of the 
high non-sepsis attributable mortality of critical illness in these subsets (eTable-3) 
(20).  
Our analysis highlights the need for explicitly estimating trial specific AFsepsis 
to inform sample size calculations. The challenge is to determine the comparator 
population for these estimations. For example, the intervention could either reduce 
the risk of death from sepsis to those experienced by similar patients with the same 
site of infection but without organ dysfunction (such as uncomplicated urinary tract 
infection) or the intervention would counteract all the effects of the sepsis state, 
returning the patient their pre-sepsis health state. The control group chosen should 
match the target state of the treated patient population the intervention is expected to 
achieve and the trial objectives (Table-2). 
The AFsepsis approach complements other recent recommendations about 
trial design including susceptibility to tested treatment and likelihood of outcome [6, 
9], by identifying, empirically, patients at the greatest risk of dying from sepsis. 
Identifying patients with a mechanism that is responsive to the tested intervention is 
referred as predictive enrichment, with the assumption that the target biological 
effect of sepsis is a major contributor for death. This principle has been 
demonstrated using the association between mortality and response to PEEP in 
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Acute Respiratory Distress Syndrome patients [28] and for corticosteroid 
responsiveness in septic shock [29].  These methods are particularly challenging in 
critical care, as markers of treatment response that are in the causal biological 
network[30] of the tested intervention and independently associated with higher 
mortality, are difficult to ascertain. For example, intravenous immunoglobulin (IVIg) 
trials test effects of immunomodulation and normalisation of low immunoglobulin 
levels in sepsis, with no consistent benefits [31]. However, enriching on low 
immunoglobulins alone may not overcome this [32], but enriching a sepsis 
population with combination of low immunoglobulin levels alongside raised free light 
chains implying impaired immunoglobulin production, might[33]. Prognostic 
enrichment, which uses the risk of the study outcome as predicted by baseline 
covariates, relies on the observation that treatment effects usually exert a fixed 
relative risk of benefit regardless of the individual patient’s risk of the outcome.  
Patients at the greatest risk of the outcome derive the greatest, and therefore, the 
easiest to measure, benefit[34]. This method was tried, unsuccessfully, in the 
evaluation of activated protein C in patients with both low[35] and high risk of 
death[36].  More sophisticated approaches to incorporating baseline risk of outcome 
in to trial design have been proposed[37]. We also show how the baseline risk of 
death is also important as patients at the highest risk of death also have the highest 
AFsepsis (see Figure-3). 
Our study has strengths and limitations. We estimate AFsepsis for the first 
time using the Sepsis-3 criteria. We report an AFsepsis range using two control 
populations. The upper limit of the range highlights that AFsepsis is unlikely to be 
100% as similarly ill patients have high mortality even when not septic because 
sepsis, unlike, say myocardial infarction, does not usually occur in previously healthy 
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patients. We used a high-quality representative national database that had enough 
patients to use a strict 1:1 matching criteria and matched >99% of the sepsis cohort 
to non-sepsis ICU controls to reduce confounding in the sepsis and mortality 
association. We then used AFsepsis to generate isopleths of control group mortality 
for different RRR to illustrate the impact of knowing AFsepsis during trial design, 
which is novel. Although we have highlighted the AFsepsis conceptual principles 
using original data, with two different controls and propensity methods, we have not 
formally tested this in a completed trial.  Despite our use of a multivariate propensity 
model, residual confounding is certainly a concern.  Failure to account for residual 
confounders might make the estimated AFsepsis even smaller than estimated in this 
study.  Our analysis uses ICU controls and these controls might have higher 
mortality than hospital based non-septic controls, due to their underlying illness.  Our 
analysis is relatively robust to this concern as we did not incorporate acute 
physiologic derangement in our propensity score, however, a theoretic sepsis 
therapy that might avoid ICU admission entirely would need an AFsepsis analysis 
using hospital non-septic controls (Table-2). Despite this limitation, our analyses are 
consistent with the AFsepsis estimates of ICU acquired secondary sepsis that 
yielded attributable fractions between 10.9% and 21.1%[15], and ventilator 
associated pneumonia attributable fraction between 4.4% and 13%[16, 38].   
Our analysis raises a number of important future studies.  First, as magnitude 
of sepsis-related mortality is influenced by the site of infection, organ dysfunction 
characteristics and the end point chosen in trials (such as 28-days or 90-days), the 
trial specific AFsepsis is also likely to vary [14, 39].  Like baseline risk of death, there 
is likely to be a heterogeneity of AFsepsis within any given trial population and lends 
itself to similar analytic solutions [5]. Our analysis highlights the need to reconsider 
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the expected magnitude of RRR chosen for sample size calculations in sepsis trials.  
Given the potentially large sample size requirements, when either the AFsepsis is 
low or the likely RRR in a trial population is low, we illustrate the need for efficient 
trial designs in critically ill patients to prioritize finding effective treatments over 
evaluating single therapy [40].  
Conclusions 
Using AFsepsis principles, we illustrate the impact of AFsepsis on sample size 
estimations in sepsis trials.  Given that AFsepsis could be substantially less than 
100%, estimating AFsepsis based on trial specific eligibility criteria to inform sample 
size calculations could be another useful additional step in designing sepsis trials. 
Our results are best considered as proof of concept that requires validation.  
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Figure legends 
Figure-1: Range of AFsepsis estimated using control populations  
The fraction of deaths attributable to the sepsis exposure (AFsepsis) = [(Deaths in 
sepsis – Deaths in non-sepsis)/Deaths in sepsis] ascertained using proportions. 
Propensity for sepsis logistic regression models[22] can be used to derive AFsepsis 
and AFseptic shock. Bar graphs show the mortality difference between sepsis/septic 
shock compared first to propensity matched ICU-non-sepsis controls and second to 
age-sex matched general population controls. AFE = AFsepsis and AFseptic shock 
respectively; RD = risk difference. Further details of study population and propensity 
models are provided in Table-1. Model-1 represents propensity model for sepsis. 
Model-2 represents propensity model for septic shock. 
 
Figure-2: Sample size estimations based on different AFsepsis, effective RRR 
and control group mortality for sepsis RCTs 
The figure shows the sample size estimations for different treatment effectiveness 
amongst attributable deaths (effective RRR) and different control group mortality for 
80% power and 5% alpha.  The dot plots are placed at a fixed point on all four 
graphs based on actual RRR used for sample size estimation and sample size per 
group reported in trials (see eTable-4).  Each curve represents a different control 
group mortality and sample sizes above the curve are adequately powered for the 
corresponding control group mortality. Each graph represents a different AFsepsis 
ranging from our lowest estimate of 15% (Figure 2a), median estimate of 54% 
(Figure 2b) and the highest estimate of 93% (Figure 2c). The maximum overall RRR 
that is observable if the intervention prevented all sepsis deaths in Figure2a is 15%, 
in Figure 2b is 54% and in Figure2c is 93%, which is equivalent to an effective RRR 
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of 1.0, that is, the treatment is perfect (effective RRR=1). It is important to highlight 
using Figure 2d (100% AFsepsis plot) that all these trials were adequately powered 
across a range of expected mortality under, standard sample size estimation 
approaches. These graphs also highlight that the sample size requirements will vary 
by AFsepsis for the same control group mortality. 
 
Figure-3:  Illustrating the utility of AFsepsis estimation 
The figure shows the sample size estimations for a fixed control arm mortality 
(Figure3a=30% and Figure3b=50%). X-axis refers to different treatment 
effectiveness among the attributable deaths (effective RRR).  Y-axis is sample size 
estimation as a function of changing AFsepsis and effective RRR. Two key principles 
are highlighted by this figure. First, if we have a fixed control group mortality and a 
fixed effective RRR, the sample size will increase with decrease in AFsepsis. For 
example, in a trial with control group mortality of 30% with RRR of 20%, the sample 
size per group would be 859, 1554, 3554 and 14,437 as AFsepsis in the trial 
population changes from 100%, to 75%, to 50% and 25% respectively. Second, data 
from a completed trial and a control population registry can be used to estimate a 
trial specific AFsepsis to determine the what effective RRR might have been missed. 
The reason being, with AFsepsis approach, patients’ risk of target outcome 
specifically attributed to sepsis are identified. The notion that there is likely to be trial 
specific AFsepsis is supported by the higher AFseptic shock shown in Figure-1, 
explained by differences in septic shock criteria. Abbreviation = relative risk 
reduction (RRR). 
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Table legends 
Table-1 Baseline characteristics of sepsis, septic shock, and corresponding 
non-sepsis propensity matched control populations to derive sepsis/septic 
shock attributable fraction 
PMH = past medical history of severe comorbidities; N= number; %= proportion; SD 
= standard deviation; APACHE II = Acute Physiology And Chronic Health Evaluation 
II method and score; RD = risk difference; RR = relative risk;  95% CI = 95% 
confidence interval; Attribution fraction (AFsepsis and AFseptic shock );p = p value; std 
diff = standardised difference between the treated and not treated in propensity 
models used for balance checking; NMV = not matched variable 
 
Table-2 Control populations and rationale 
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Table-1 Baseline characteristics of sepsis, septic shock, and corresponding non-sepsis propensity matched control populations to derive 
sepsis/septic shock attributable fraction 
 
 Model-1 Model-2 
Parameter Sepsis  Non-sepsis Std Diff Septic Shock Non-sepsis Std Diff 
Matched (N; %) 179,704/179,717 (99.9%)  36,833/36,838 (99.9%)  
Age (years; mean (SD) 63.7 (16.4) 63.8 (16.5) -0.004 65.5 (14.9) 65.5 (14.9) 0.000 
Sex Female N (%) 81,553 (45.4%) 81,460 (45.3%) -0.001 16,556 (45.0%) 16,556 (45.0%) -0.000 
Ethnicity N (%) 
White 
Asian 
Black 
Other 
Mixed 
Not stated 
 
162,147 (90.2%) 
6,718 (3.7%) 
3,988 (2.2%) 
2,082 (1.2%) 
822 (0.5%) 
3,947 (2.2%) 
 
159,792 (88.9%) 
7,213 (4.0%) 
4,625 (2.6%) 
2,383 (1.3%) 
843 (0.5%) 
4,848 (2.7%) 
NMV 
 
32,906 (89.3%) 
1,539 (4.2%) 
813 (2.2%) 
507 (1.4%) 
177 (0.5%) 
891 (2.4%) 
 
33,069 (89.8%) 
1,414 (3.8%) 
853 (2.3%) 
433 (1.2%) 
152 (0.4%) 
912 (2.5%) 
NMV 
PMH present N (%) 35,988 (20.0%) 35,286 (19.6) 0.010 7,527 (20.4%) 7,527 (20.4%) -0.000 
Comorbidity N (%) 
Cardiovascular 
Respiratory 
Liver 
Renal 
Metastatic disease 
Hematologic 
Immunosuppressed 
 
3,097 (1.7%) 
7,777 (4.3%) 
4,160 (2.3%) 
3,754 (2.1%) 
4,407 (2.5%) 
6,628 (3.7%) 
14,947 (8.3%) 
 
4,319 (2.4%) 
4,575 (2.6%) 
7,454 (4.2%) 
5,619 (3.1%) 
5,243 (2.9%) 
3,923 (2.2%) 
11,072 (6.2%) 
NMV 
 
662 (1.8%) 
1,038 (2.8%) 
1,183 (3.2%) 
731 (2.0%) 
1,000 (2.7%) 
1,558 (4.2%) 
3,241 (8.8%) 
 
769 (2.1%) 
1,259 (3.4%) 
1,334 (3.6%) 
1,037 (2.8%) 
1,067 (2.9%) 
1,040 (2.8%) 
2,660 (7.2%) 
NMV 
Surgical status N (%) 
Medical 
Elective surgical 
Emergency surgical 
 
135,760 (75.5%) 
7,591 (4.2%) 
36,353 (20.3%) 
 
135,626 (75.5%) 
7,591 (4.2%) 
36,487 (20.3%) 
-0.002 
 
27,475 (74.6%) 
773 (2.1%) 
8,585 (23.3%) 
 
27,475 (74.6%) 
773 (2.1%) 
8,585 (23.3%) 
0.000 
APACHE II Physiology score 13.7 (6.0) 12.2 (6.5) NMV 17.1 (6.6) 12.5 (6.2) NMV 
APACHE II score 18.5 (6.9) 16.9 (7.4) NMV 22.1 (7.2) 18.5 (6.9) NMV 
Hospital mortality N (%) 57,319 (31.8%) 48,587 (27.0%) - 20,439 (55.5%) 10,261 (27.9%) - 
RD (95% CI) 
RR (95% CI) 
AFsepsis or septic shock (%) 
P - value 
4.9% (4.6% – 5.2%) 
1.18 (1.17 – 1.19) 
15.2% (14.4% – 16.1%) 
<0.001 
- 
27.6% (26.9% – 28.3%) 
1.99 (1.95 – 2.03) 
49.8% (48.8% – 50.7%) 
<0.001 
- 
Table-2: Control populations and rationale 
 
Control 
description 
Comment on control group Advantages and limitations of control group Trial design implication for AFsepis 
estimate for the control group 
ICU non-
sepsis 
controls 
 
This control group represents a broader 
patient population without sepsis. 
 
These patients therefore will have a risk 
of death that is determined by their illness 
and risk due to being managed in critical 
care. 
Accounts for the risk of critical care management. 
 
Conservative estimate of AFsepsis due to ‘risk of 
death from primary illness that required admission’ 
– provides lower boundary of likely risk reduction, 
irrespective of the potency of the intervention 
Intervention is expected to reduce the risk 
of death to ‘non-sepsis critical illness’. 
 
This represents worst case scenario for a 
new intervention tested in a trial. 
 
 
Hospitalised 
infected 
controls 
This control group represents a patient 
population who have infection but without 
sepsis. 
 
These patients represent, those with 
either in an earlier stage of illness or do 
not develop organ dysfunction during the 
entire hospital stay following an infection. 
Accounts for the ‘all the dysregulated host 
response to infection related organ dysfunction’ 
and the risk of death associated with 
hospitalisation but without the critical care related 
and infection related risks of death 
 
Conceptually elegant model for trial design 
 
Probability of any single intervention reducing this 
magnitude of illness specific risk by altering a 
single biological mechanism is low 
Intervention is expected to reduce the risk 
of death to that expected in hospitalised 
infected patients. 
 
 
Hospitalised 
non-infected 
controls 
This control group represents a broader 
patient population who are hospitalised 
for non-infection reason. 
 
These patients therefore will have a risk 
of death that is determined by their illness 
and risk due to being managed in 
hospital. 
Accounts for the ‘all the dysregulated host 
response to infection related organ dysfunction, 
risk of death due to infection and the risk of death 
associated with hospitalisation but without the 
critical care related risk of death 
 
Probability of any single intervention reducing this 
magnitude of illness specific risk by altering a 
single biological mechanism is low  
Intervention is expected to reduce the risk 
of death to that expected in hospitalised 
non-infected patients 
Age and Sex 
matched 
general 
population 
controls 
This control group represents general 
population risk. 
 
 
Liberal estimate of AFsepsis as these controls only 
account for age and sex effects on outcome. 
As comorbidities are not accounted for, this would 
be an overestimate of the intervention effect. 
Intervention is expected to reduce the risk 
of death to ‘general population, matched 
on age and sex. 
 
This represents best case scenario for a 
new intervention tested in a trial. 
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Shankar-Hari M, Harrison D, Rowan K, Rubenfeld GD. Estimating attributable fraction of sepsis 
to inform clinical trials. 
 
eMethods: Further description of study data source and methods 
 
eTable-1: Operationalisation of Sepsis-3 Definitions 
Table summarises the operationalisation of Sepsis-3 definitions. This has been recently reporting 
using the dataset used for this study.  
Shankar-Hari M et al. Epidemiology of sepsis and septic shock in critical care units: comparison 
between Sepsis-2 and Sepsis-3 populations using a national critical care database [21]. 
 
eTable-2: AFsepsis after excluding patients who had withdrawal of treatment within 12 hours 
*AFsepsis and AFseptic shock were estimated using a posthoc sensitivity analysis after excluding 
patients with active treatment withdrawn 12 hours of ICU admission. 
 
eTable-3: Summary of inclusion and exclusion criteria in the trials identified 
 
eTable-4: Summary of sample size calculations in trials identified to compare with the 
AFsepsis model 
The trials are listed by publication year starting with year 2015. The original reported sample size 
calculations were extracted and presented in Figure-2 and in this table. We did not use the reported 
adjustments during interim analyses. RRR was estimated using reported sample size calculations 
when not explicitly stated. *Lower limit of reported range was used to estimate RRR from 6% - 7% 
absolute risk reduction used in the trial to estimate sample size. Display code – identifies the trial in 
Figure-2. RRR = relative risk reduction; EGDT = Early goal directed therapy; Hb = Hemoglobin; 
Proportions were rounded to whole numbers without decimals.  
 
eFigures:  
eFIgure-1: Flow diagram for patients in the study 
 
eFigure-2: Flow diagram for trial selection 
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eMethods: Further description of study data source and methods 
For sepsis cases and non-septic critically ill controls, we used the consecutive admissions 
between January 2011 and December 2015 recorded in the Intensive Care National Audit & 
Research Centre (ICNARC) Case Mix Programme Database (CMPD) [22], The ICNARC-CMPD 
is the national clinical audit for adult general ICUs in England. For consecutive ICU 
admissions, trained data collectors collect sociodemographic, comorbidity, and physiologic 
data to precise rules and definitions, during the first 24 hours following admission to ICU. 
Diagnostic data are determined clinically and coded using the hierarchical ICNARC Coding 
Method with 5 tiers [22]. A code is automatically generated that represents a patient’s 
clinical diagnosis route through this hierarchy. Collected data undergo extensive local and 
central validation prior to pooling into the CMPD. The CMPD has been independently 
assessed to be of high quality. Support for the collection and use of these data has been 
obtained under Section 251 of the National Health Service Act 2006 (PIAG 2–10(f)/2005). 
Additional details of propensity models  
We used nearest neighbour 1:1 greedy matching without replacement with caliper 
bandwidth specified as 0.1 standard deviation of the propensity score to generate a 
conditional probability of sepsis [23]. We checked balance of all the matched covariates 
using standardized differences of mean [23].  
Rationale for sensitivity analysis 
As a sensitivity analysis and to reflect frequent exclusion criteria in clinical trials, we 
ascertained AFsepsis and AFseptic shock in patients without severe comorbidities using 
propensity models with age, sex, and surgical status as covariates to confirm our 
assumption that comorbidity effect is accounted for by the main propensity model, by 
excluding all patients with comorbidities from the analysis set prior to deriving these 
models. We conducted a post hoc sensitivity analysis excluding patients who had 
withdrawal of treatment decision made within 12 hours of ICU admission. The rationale 
being that these patients would be excluded from sepsis and septic shock clinical trials.  
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eTable-1: Operationalisation of Sepsis-3 Definitions 
 
Criteria Sepsis-3 
Infection Reason for ICU admission 
Organ dysfunction 
SOFA score of 2 or more in any one organ system or SOFA 
score of one in two or more organ systems 
Sepsis Sepsis = Infection AND >=2 SOFA points 
Septic shock Infection AND cardiovascular SOFA>=2 AND serum lactate 
concentrations >2mmol/L 
 
 
eTable-2: AFsepsis and AFseptic shock after excluding patients who had withdrawal of treatment within 12 hours 
 
Parameter Sepsis  
N = 179,700 
Non-sepsis 
N=179,702 
Septic Shock 
N=36,832 
Non-sepsis 
N=36,833 
Withdrawal of treatment N (%) 24,427 (13.6%) 19,963 (11.1%) 10,197 (27.7%) 4,034 (11.0%) 
Time to withdrawal of 
treatment median (IQR) days 
2.9 (1.0 – 7.8) 2.1 (0.8 – 4.9) 2.5 (1.0 -7.2) 2.5 (0.9 – 5.9) 
Withdrawal of treatment within 
12 hours of ICU admission N (%) 
3,077 (1.7%) 2,923 (1.7%) 1,188 (3.2%) 563 (1.5%) 
*RD (95% CI) 
*RR (95% CI) 
*AFsepsis or septic shock (%) 
P - value 
7.4% (6.7% – 8.1%) 
1.21 (1.19 – 1.23) 
17.2% (15.7% – 18.9%) 
<0.001 
29.4% (27.9% – 31.0%) 
1.80 (1.74 – 1.87) 
44.5% (42.6% – 46.4%) 
<0.001 
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eTable-3: Inclusion and exclusion criteria in the trials identified 
 
N Trial ID 
Inclusion criteria Exclusion criteria 
1 Mouncey PR et al (2015)[8] 
Adults (≥18 years of age) were eligible if within 6 hours after presentation to the emergency 
department they had a known or presumed infection, two or more criteria of the systemic 
inflammatory response syndrome, and either refractory hypotension (systolic blood pressure, <90 
mm Hg; or mean arterial pressure, <65 mm Hg, despite resuscitation with at least 1 litre of 
intravenous fluids within 60 minutes) or hyperlactatemia (blood lactate level, ≥4mmol per litre) 
Age less than 18 years; pregnancy; Primary diagnosis of: acute cerebral vascular event, acute 
coronary syndrome, acute pulmonary oedema; status asthmatics; major cardiac arrhythmia (as 
part of primary diagnosis); seizure; drug overdose; injury from burn or trauma; hemodynamic 
instability due to active gastrointestinal haemorrhage; Requirement for immediate surgery; 
Known history of AIDS; Do-not-Attempt-Resuscitation (DNAR) order; Advanced directives 
restricting implementation of the resuscitation protocol; Contradiction to: central venous 
catheterization or to blood transfusion; Attending clinician deems aggressive resuscitation 
unsuitable; Transferred from another in-hospital setting; Not able to commence resuscitation 
protocol within one hour of randomization or complete six hours of protocol treatment from 
commencement 
2 Payen DM et al (2015)[3] 
Patients with severe sepsis or septic shock and underwent emergency surgery to treat visually 
confirmed peritonitis. In order to distinguish between hypotension resulting from the effect of 
sedation, shock had to occur or persist within 10 h after surgical proce- dure with a duration of at 
least 2 h. Shock was classically defined as a hypotension resistant to fluid administration 
requiring norepinephrine or other vasopressor 
Age < 18 years; protected adult under law; Pregnancy; Moribund status or life expectancy lower 
than 48h; Aplasia related to chemotherapy or malignancy; Non-surgically treated abdominal 
sepsis; Absence of intra-abdominal organ perforation ; A mesenteric ischemia without 
perforation; Trauma-induced gastro-intestinal perforation; Appendicle peritonitis; A cirrhosis Child 
C; A prolonged cardiac arrest within 72 hours before surgery; A contraindication to the use of 
heparin for hemoperfusion (risk of bleeding and / or history of heparin induced 
thrombocytopenia);  Discovery of an advanced stage of cancer; Additionally, the patients who 
refused to participate even after inclusion by the emergency process and who refused to 
participate after recovery were excluded from the study analysis. 
 
3 Yealy DM et al (2014)[11] 
We recruited patients in the emergency department in whom sepsis was suspected according to 
the treating physician, who were at least 18 years of age, who met two or more criteria for 
systemic inflammatory response syndrome and who had refractory hypotension or a serum 
lactate level of 4 mmol per liter or higher. 
Patients who had: a primary diagnosis of acute cerebral vascular event, acute coronary 
syndrome, acute pulmonary edema, status asthmaticus, major cardiac arrhythmia, active 
gastrointestinal hemorrhage, seizure, drug overdose, burn or trauma; a requirement for 
immediate surgery; a known CD4 count <50/mm2; an advance directive that would restrict 
protocol implementation; a contraindication to central venous catheterization; a high likelihood of 
refusing blood transfusion (e.g., Jehovah’s Witness); a treating physician who deemed 
resuscitation to be futile; on-going participation in another interventional study; known pregnancy, 
or; been transferred from another hospital. 
4 Peake SL et al (2014)[10] 
Eligibility criteria were a suspected or confirmed infection, two or more criteria for a systemic 
inflammatory response and evidence of refractory hypotension or hypoperfusion. Refractory 
hypotension was defined as a systolic blood pressure of less than 90 mm Hg or a mean arterial 
pressure of less than 65 mm Hg after an intravenous fluid challenge of 1000 ml or more 
administered within a 60-minute period. Hypoperfusion was defined as a blood lactate level of 4.0 
mmol per liter or more. 
Patients were not eligible for enrolment if they met one or more of the following criteria: age < 18 
years; contraindication to central venous catheter insertion in the superior vena cava; 
contraindication to receiving blood products; hemodynamic instability due to active bleeding; 
underlying disease process with a life expectancy < 90 days; death deemed imminent and 
inevitable; documented limitation of therapy order restricting implementation of the study protocol 
or aggressive care deemed unsuitable by the treating clinician; in-patient transfer from another 
acute health care facility; confirmed or suspected pregnancy; inability to commence EGDT within 
one hour of randomization or deliver EGDT for 6 hours 
5 Holst LB et al (2014)[9] 
(1) At least 2 SIRS criteria;  AND (2) suspected focus of infection as either: An organism grown 
in blood or sterile site OR An abscess or infected tissue (e.g. pneumonia, peritonitis, urinary tract, 
vascular line infection, soft tissue, etc). AND (3) hypotension (Systolic blood pressure < 90 
mmHg or mean arterial pressure < 70 mmHg) despite fluid therapy OR vasopressor/inotrope 
infusion to maintain blood pressure.  
 
Documented wish against transfusion OR Previous serious adverse reaction with blood products, 
excl. transfusion-associated circulatory overload OR  Presence of acute myocardial ischemia 
OR (defined as: patients diagnosed with acute myocardial infarction (ST-elevation myocardial 
infarction or non-ST elevation myocardial infarction) or unstable angina pectoris during current 
hospital admission, according to the criteria in the clinical setting in question (e.g. elevated 
biomarkers, ischemic signs on ECG, clinical presence) AND the patient has received treatment, 
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initiated during current hospital admission, as a consequence of this (reperfusion strategies 
(PCI/thromobolysis) or initiation/increased antithrombotic treatment)). Life-threatening bleeding 
OR (defined as: (1) Presence of hemorrhagic shock, as judged by research or clinical staff. OR 
(2) the need for surgical procedure, incl. endoscopy to maintain hemoglobin levels); Red cell 
transfusion during current ICU admission OR Withdrawal from active therapy or brain death OR 
Acute burn injury - regardless of degree and burn surface area OR  Lack of informed consent   
 
6 Afzar P at al (2014)[13] 
Presence of septic shock within less than 6 hours (onset defined by the time of introduction of 
catecholamines) 
  A minimum vasopressor infusion rate of 0.1μg/Kg/min 
The criteria for septic shock were the official criteria of the American College of Chest 
Physicians / Society of Critical Care Medicine, i.e.: 
sepsis: patients with a systemic inflammatory response syndrome plus a suspected or 
Septic shock was defined as sepsis plus arterial hypotension (systolic blood pressure < 90 mm 
Hg) refractory to fluid resuscitation (minimum 30 mL/kg within 6 hours prior to the start of 
catecholamines) and requiring vasopressor support. The consent of the subject was obtained 
from the patient if his or her condition permitted, from family or person of trust if present. As last 
recourse, the procedure for inclusion in emergency situations was applied in the absence of the 
family or next of kin. 
"Legally protected" adult patient., (i.e. These patients are protected by law and cannot be 
included in RCT e.g. patients who have no guardian, are convicted felons and in jail etc.; Person 
not affiliated with or non-beneficiary of a health care system.; Minors and pregnant women; 
Patient currently in an exclusion period following participation in another biomedical study; 
Participation in another interventional study with “28 day mortality” as primary endpoint or one of 
the secondary endpoints of SEPSISPAM; Decision. not to resuscitate. 
7 Caironi O et al (2014) 
Proved or suspected infection in at least one site: a) lung; b) abdomen; c) genito-urinary tract; d) 
other (blood, skin and soft tissue, central nervous system, bones and joints, cardiac system, 
catheter-related infection, other AND two or SIRS criteria  AND Presence of at least a severe and 
acute sepsis-related organ dysfunction, as measured by the modified Sequential Organ Failure 
Assessment (SOFA) score of 1 or more on any one of the organ systems 
 
Age below 18 years; Terminal state; Known adverse reaction to albumin administration; Severe 
sepsis or septic shock in patients after proved or suspected head injury, clinically Active; 
Congestive heart failure (New York Heart Association class of 3 or 4); Pathological conditions in 
which albumin administration is clinically indicated (hepatic cirrhosis with ascites, intestinal 
malabsorption syndrome, nephrotic syndrome, burns); More than 24 hours since inclusion criteria 
were met; Religious objection to the administration of human blood products; Inclusion in other 
experimental studies 
8 Ranieri VM et al (2012)[17] 
Inclusion criteria to obtain informed consent = 1. Aged C 18 years old; 2. Must have an infection 
requiring intravenous antimicrobial therapy; 3. Must meet at least two of the four systemic 
inflammatory response syndrome (SIRS) criteria. 4. Must have septic shock, defined as:  
(a) The patient must have received intravenous fluid resuscitation of C 30 mL/kg administered 
within the time period spanning the 4 hours before and 4 hours after initiation of vasopressor 
therapy.  (b) The patient must have a continuous requirement for at least one of the vasopressors 
listed below at the dose shown below for at least four hours:  Norepinephrine C 5 mcg/min 
Dopamine C 10 mcg/kg/min Phenylephrine C 25 mcg/min Epinephrine C 5 mcg/min Vasopressin 
C 0.03 units/min ; (c) The patient must meet at least 1 of the following criteria consistent with 
hypoperfusion during the 36 hours prior to study entry:  Metabolic acidosis: base deficit C 5.0 
mmol/L or venous bicarbonate \ 18 mmol/L or lactate C 2.5 mMol/L.  Urine output \ 0.5 mL/kg h-1 
for 1 hour or a 50% increase in creatinine from a known baseline level.  Acute hepatic 
dysfunction: AST or ALT [ 500 IU/dL or bilirubin [ 2 g/dL.  Inclusion criterion to proceed to 
randomisation 5. Patients must remain vasopressor dependent throughout the  
pretreatment period and through the time of randomisation with the goal of maintaining a systolic 
blood pressure of approximately 90 mm Hg or higher or a mean arterial pressure of 65 mm Hg or 
higher with reasonable attempts made to wean the patient from vasopressor support, if 
applicable. (Note: dopamine at doses \ 5 mcg/kg/min does not fulfil the criteria for vasopressor 
dependency.)  
 
 < 18 years of age;  Does Not Have Evidence of Infection; Does Not Satisfy SIRS Criteria;  
Does Not Meet Septic Shock Criteria; Has Not Remained Vasopressor Dependant; Vasopressor 
Therapy for > 24 Hours; Sepsis Induced Organ Dysfunction > 36 Hours; Single Organ 
Dysfunction and Recent Surgery (within last 30 days); Post-op < 12 hours, Evidence of Bleeding, 
or Planned Surgery; Platelet Count < 30x 109/L; INR > 5.0; Active Internal Bleeding or Increased 
Risk for Bleeding; Receiving or Concurrent Need for Bleeding Risk Medications; Not Expected to 
Survive 28 Days due to Pre-existing Condition; Moribund & Death is Perceived to be Imminent; 
Not Committed to Aggressive Management; Received DrotAA within Last 30 Days; Pregnant or 
Lactating & the Milk is to be Ingested by the Newborn; Fail to Give Written Informed Consent; 
Participating in Competing Study of Investigational Drug; Incomplete Information available; 
Condition Improving; Second Sepsis Episode; Site On Hold; Pharmacy Issue; Not in ICU 
(Monitored Unit) 
9 Huh JW et al (2011)[20] Onset of septic shock within 6 h and relative adrenal insufficiency, defined as an increase in cortisol level of <9 mg/dL or a basal cortisol level of <25 mg/dL. 
Advanced cancer, immunosuppression, previous treatment with corticosteroids, refusal of the 
attending staff or patient family and absence of adrenal insufficiency 
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10 De Backer D et al (2010)[19] 
All patients 18 years of age or older in whom a vasopressor agent was required for the treatment 
of shock were included in the study. 
Patients were excluded if they were younger than 18 years of age; had already received a 
vasopressor agent (dopamine, norepinephrine, epinephrine, or phenylephrine) for more than 4 
hours during the current episode of shock; had a serious arrhythmia, such as rapid atrial 
fibrillation (>160 beats per minute) or ventricular tachycardia; or had been declared brain-dead. 
11 Patel GP et al (2010)[4] 
Eligible patients had to be in shock (MAP <60 mmHg and/or systolic blood pressure <90 mmHg) 
after adequate fluid resuscitation, as determined by a CVP greater than 8 mmHg for non-
mechanically ventilated patients (12 to 15 mmHg for patients requiring mechanical ventilation) 
and require the administration of a vasopressor for management.  
Patients were excluded from the study if they were found to have alternative causes of their 
shock (i.e., hypovolemic, haemorrhagic, cardiogenic, anaphylactic, and/or obstructive shock) or 
another cause of their SIRS. Patients who were allergic to DA or NE were excluded, as were 
patients who were on vasopressors for more than 6 h before enrolment 
12 Palizas F et al (2009)[5] 
All adult patients fulfilling criteria for septic shock according to the ACCP/SCCM Consensus 
Conference within 48 hours of ICU admission were considered and selected if they were in a 12-
hour time window.  
Exclusion criteria were: terminal illness with the patient expected to die within 28 days, 
irreversible neurologic impairment, and contraindication for nasogastric tube placement. 
13 Stephens DP et al (2008)[6] 
Septic shock was defined according to the ACCP/SCCM Consensus Conference criteria and 
included the presence of sepsis, shock, and evidence of at least one other organ dysfunction. 
The inclusion criteria were adult patients ( 18 yrs of age) admitted to the ICU that met these 
criteria for septic shock who were assessed for eligibility within 24 hrs of meeting these criteria. 
The time from screening to consent and study drug administration was limited to 36 hrs.  
Patients with culture-confirmed melioidosis, hematologic malignancy, febrile neutropenia, 
myelodysplasia or congenital neutropenia, splenomegaly, acute myocardial infarction in the 
previous 24 hrs, pregnancy, known hypersensitivity to G-CSF, known objection to participation, 
previous transplantation, active orders limiting treatment, and patients with an expected survival 
of  24 hrs, patients previously enrolled or who had received G-CSF within the previous month 
14 Sprung CL et al (2008)[15]   
15 Russell JA et al (2008)[12] 
Patients older than 16 years of age who had septic shock that was resistant to fluids (as defined 
by lack of response to 500 ml of normal saline or a requirement for vasopressors) and low-dose 
norepinephrine were considered for enrolment. 
unstable coronary syndrome (acute myocardial infarction during this episode of shock based on 
the combination of history, electrocardiogram, and enzyme changes (as defined by investigator); 
greater than 24 hours had elapsed since the patient met entry criteria; use of open-label 
vasopressin for blood pressure support during the current hospital admission; malignancy or 
other irreversible disease or condition for which six-month mortality was estimated to be ≥ 50%; 
acute mesenteric ischemia either proven or suspected. A patient could be excluded by the 
investigator if, in their judgment, the condition was strongly suspected but not proven by 
conventional criteria or the attending physician had initiated presumptive therapy, 
death anticipated within 12 hours; underlying chronic heart disease (NYHA class III or IV) and 
shock; physician and team were not committed to aggressive care; severe hyponatremia (serum 
sodium < 130 mmol/L); traumatic brain injury(GCS<8prior to onset of sepsis); Raynaud’s 
phenomenon, systemic sclerosis or vasospastic diathesis, pregnancy(positiveserumβ-HCG). 
16 Werdan K et al (2007)[14] 
Four of nine positive sepsis criteria: Temperature; White blood cell count  12 G/L or  3.5 G/L 
Heart rate>100 beats/min; Respiratory rate>28 breaths/min or FIO2>0.21; Mean arterial 
pressure<75 mm Hg; In case of invasive hemodynamic moni- toring (not obligatory for study 
partici- pation), cardiac index  4.5 L/min/m2 or systemic vascular resistance  800 dyne/ sec/cm5 
Platelets<100 G/L; Positive blood cultures; Clinical evidence of sepsis (surgical or invasive 
procedure during the preceding 48 hrs or presence of an obvious septic focus); A sepsis score of 
12–27, rating several variables categorized into four classes according to Elebute and Stoner: 
local signs of infection, pyrexia, organ failure, and labo- ratory values 
3. An APACHE II score of 20 –35 as a measure of the degree of disease severity 
Not provided with the main paper. Readers are referred to a previous publication 10 years ago – 
by Pilz G, Fateh-Moghadam S, Viell B, et al: Supplemental immunoglobulin therapy in sepsis and 
septic shock—Comparison of mortality under treatment with polyvalent i.v. immunoglobulin 
versus placebo. Proto- col of a multicenter, randomized, prospec- tive, double-blind trial. Theor 
Surg 1993; 8:61– 83 
17 Annane D et al (2007)[16] 
evidence of infection; at least two of the four criteria for systemic inflammatory response 
syndrome (temperature above 38°C or below 36°C, heart rate above 90 bpm, respiratory rate 
above 20 cycles per min and arterial CO2 tension below 32 mm Hg or need for mechanical 
ventilation, polymorphonuclear neutrophil count above 12×109 cells per L or below 4×109 cells 
per L); and at least two signs of tissue hypoperfusion or organ dysfunction. These signs were 
defined as a ratio of arterial oxygen tension over inspired fraction of oxygen of less than 280 mm 
Hg (if patient was mechanically ventilated), urinary output below 0·5 mL per kg of bodyweight per 
h or below 30 mL/h (for at least 1 h), or arterial lactate concentration above 2 mmol/L, platelet 
count below 100×109 cells per L. Additionally, patients had to meet the three following criteria for 
less than 24 h: systolic blood pressure below 90 mm Hg or mean blood pressure below 70 mm 
Reasons for exclusion were pregnancy; evidence of obstructive cardiomyopathy, acute 
myocardial ischaemia, or pulmonary embolism; advanced stage cancer, haematological 
malignancy, or AIDS with a decision to withhold or withdraw aggressive therapies; persistent 
(longer than a week) polymorphonuclear neutrophil count of less than 0·5×109 cells per L; and 
inclusion in another clinical trial. 
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Hg; administration of fluid bolus of at least 1000 mL or capillary wedge pressure between 12 and 
18 mm Hg; and need for more than 15 μg per kg of bodyweight per min of dopamine or any dose 
of epinephrine or norepinephrine. 
18 Angstwurm MWA et al (2007)[7] 
Males and females>18yrs with an Acute Physiology and Chronic Health Evaluation (APACHE) III 
score (22)  70 and at least two of the following criteria (23): 
Rectal body temperature >38°C or hypothermia <36°C; Heart rate>90 beats/min; Respiratory 
frequency >20 and PaCO2 mm Hg >4.3 kPa; Leukocytes  12,000/ L or  4 000/ L or 10% 
immature leukocytes; Decrease of platelet count  50% within the first 24 hrs or platelets 150,000/ 
L at admission; Admission into the study after diagnosis within 24 hrs; Beginning of treatment 
within 1 hr after inclusion; Informed consent either from the patient or the relative/close friend 
Pregnancy; Missing informed consent of the patient or the relative/intimate friend of the patient; 
Withdrawal of informed consent by patient or next of kin after inclusion into the study; 
Participation in any other clinical trial cur- rently or within the last 30 days; Prior participation in 
this clinical trial; Cerebral injury due to hypoxia after cardio- pulmonary resuscitation; Primary 
concomitant disease with an ex- pected high mortality within 2 months; Do-not-resuscitate code; 
Malignant primary disease as the cause of SIRS or sepsis, for example, agranulocytosis as a 
result of chemotherapy or idiopathic bone marrow aplasia; Hemorrhagic-necrotizing pancreatitis 
with- out infectious complications 
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eTable-4: Trials identified to illustrate the AFsepsis model 
 
N Trial ID Control group Intervention group Code 
Mortality 
time 
point 
Control 
group 
mortality 
RRR Power Alpha 
Sample 
size 
per 
group 
1 Mouncey PR et al (2015)[8] Standard care EGDT A 90-day 40% 20% 80% 5% 630 
2 Payen DM et al (2015)[3] Standard care 
Polymyxin B 
hemoperfusion B 28-day 37% 54% 94% 4.5% 120 
3 Yealy DM et al (2014)[11] Standard care* EGDT C 60-day 30% - 46%* 20% 80% 5% 650 
4 Peake SL et al (2014)[10] Standard care EGDT D 90-day 38% 20% 
85% - 
90% 5% 800 
5 Holst LB et al (2014)[9] >7g/L Hb target 
>9g/L Hb 
target E 90-day 45% 20% 80% 5% 500 
6 Afzar P at al (2014)[13] 
65 – 70mmHg 
MAP target 
80 – 85mmHg 
MAP target F 28-day 45% 22% 80% 5% 400 
7 Caironi O et al (2014) Standard care Albumin>30g/L G 28-day 45% 17% 80% 5% 675 
8 Ranieri VM et al (2012)[17] Placebo 
Activated 
protein C H 28-day 35% 20% 80% 5% 750 
9 Huh JW et al (2011)[20] 
3-day 
hydrocortisone 
7-day 
hydrocortisone I 28-day 35% 50% 80% 5% 136 
10 De Backer D et al (2010)[19] Dopamine 
Nor-
epinephrine J 28-day 43% 15% 80% 5% 765 
11 Patel GP et al (2010)[4] Dopamine Norepinephrine K 28-day 60% 33% 80% 5% 120 
12 Palizas F et al (2009)[5] CI>3.0L/min/m2 
Intramucosal 
pH>7.32 L 28-day 40% 50% 80% 5% 64 
13 Stephens DP et al (2008)[6] Placebo G-CSF M Hospital 60% 38% 80% 5% 82 
14 Sprung CL et al (2008)[15] Placebo Hydrocortisone N 28-day 50% 20% 80% 5% 400 
15 Russell JA et al (2008)[12] Nor-epinephrine Vasopressin O 28-day 60% 17% 80% 5% 388 
16 Werdan K et al (2007)[14] Placebo IVIg P 28-day 30% 33% 90% 5% 400 
17 Annane D et al (2007)[16] Epinephrine 
Nor-
epinephrine + 
Dobutamine 
Q 28-day 60% 33% 95% 5% 170 
18 Angstwurm MWA et al (2007)[7] Standard care Selenium R 28-day 50% 40% 80% 5% 119 
 Summary statistics - - - - 44% (37% - 50%) 
20% (20% - 
38%) - - - 
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eFIgure-1: Flow diagram for patients in the study 
 
  Total ICU admissions 
N=654,918 
Excluded due to age<16 years, missing 
data for APACHE II score OR mortality OR 
age (N=40,409; 6.2%) 
Propensity model-1 
matched sepsis – non-
sepsis pairs 
N= 179,704 (99.9%) 
Propensity model-2 
matched septic shock – 
non-sepsis pairs 
N= 36,833 (99.9%) 
Total study cohort (N=614,509) 
Sepsis = 179,717 and Septic-shock = 36,838 
Non-sepsis = 434,792 
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eFigure-2: Flow diagram for trial selection 
 
 
 
   
 
 
 
 
 
 
 
Total Severe sepsis/septic 
shock trials included in the 
two systematic reviews[1, 
2] (N=60) 
Total non-duplicate trials 
and post 2007 trials 
included for full text review 
(N=33) 
• Duplicates = 5 
• Pre-2007 = 22 
Trials excluded with reasons (N=15) 
• Mortality not primary end point 
• Factorial or non-inferiority trial or phase II 
trials or feasibility trials or trials stopped 
early 
Total trials meeting inclusion 
criteria for data extraction 
(N=18)[3-20] 
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